Global Heart Failure Drugs Market 2018-2022
About Heart Failure Drugs
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
Technavio’s analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global heart failure drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of heart failure drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Heart Failure Drugs Market 2018-2022
Technavio recognizes the following companies as the key players in the global heart failure drugs market: Amgen, AstraZeneca, Bayer, and Novartis.
Other Prominent Vendors in the market are: Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China; and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.”
According to the report, one of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.
Amgen, AstraZeneca, Bayer, Novartis, Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook